51610 Federal Register / Vol. 74, No. 193 / Wednesday, October 7, 2009 / Notices 

ESTIMATED ANNUALIZED BURDEN

Type of respondent Type of form Number 

of respondents 

Number of responses per 

respondent 

Average burden per 

response (in 

hrs.) 

Total burden 

(in hrs.) 

Pathologist ........................................ Pathologist Invoice ........................... 50 1 5/60 4 

Pathologist ........................................ Pathologist Report ............................ 50 l 5/60 4 

Next-of-Kin ........................................ Consent Form .................................. 50 1 15/60 13 

Total ........................................... ........................................................... ........................ ........................ ........................ 21 

Dated: September 30, 2009. 

Maryam I. Daneshvar, 

Acting Reports Clearance Officer, Centers for 

Disease Control and Prevention. 

[FR Doc. E9–24155 Filed 10–6–09; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2009–D–0430] 

Draft Guidance for Industry: 

Ingredients Declared as Evaporated 

Cane Juice; Availability 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing the 

availability of the draft guidance 

entitled ‘‘Guidance for Industry: 

Ingredients Declared as Evaporated 

Cane Juice.’’ The intent of this draft 

guidance is to advise industry of FDA’s 

view that the common or usual name for 

the solid or dried form of sugar cane 

syrup is ‘‘dried cane syrup,’’ and that 

sweeteners derived from sugar cane 

syrup should not be declared on food 

labels as ‘‘evaporated cane juice’’ 

because that term falsely suggests that 

the sweeteners are juice. 

DATES: Although you can comment on 

any guidance at any time (see 21 CFR 

10.115(g)(5)), to ensure that the agency 

considers your comment on the draft 

guidance before it begins work on the 

final version of the guidance, submit 

written or electronic comments on the 

draft guidance by December 7, 2009. 

ADDRESSES: Submit written comments 

on the draft guidance to the Division of 

Dockets Management (HFA–305), Food 

and Drug Administration, 5630 Fishers 

Lane, rm. 1061, Rockville, MD 20852. 

Submit electronic comments on the 

draft guidance to http:// 

www.regulations.gov. Submit written 

requests for single copies of the draft 

guidance to Office of Nutrition, 

Labeling, and Dietary Supplements, 

Center for Food Safety and Applied 

Nutrition (HFS–820), Food and Drug 

Administration, 5100 Paint Branch 

Pkwy., College Park, MD 20740. Send 

two self-addressed adhesive labels to 

assist that office in processing your 

request. See the SUPPLEMENTARY

INFORMATION section for electronic 

access to the draft guidance. 

FOR FURTHER INFORMATION CONTACT: 

Geraldine June, Center for Food Safety 

and Applied Nutrition (HFS–820), Food 

and Drug Administration, 5100 Paint 

Branch Pkwy., College Park, MD 20740, 

301–436–1802. 

SUPPLEMENTARY INFORMATION: 

I. Background 

FDA is announcing the availability of 

the draft guidance entitled ‘‘Guidance 

for Industry: Ingredients Declared as 

Evaporated Cane Juice.’’ The intent of 

this draft guidance is to advise the 

regulated industry of FDA’s view that 

the term ‘‘evaporated cane juice’’ is not 

the common or usual name of any type 

of sweetener, including dried cane 

syrup. Because cane syrup has a 

standard of identity defined by 

regulation in 21 CFR 168.130, the 

common or usual name for the solid or 

dried form of cane syrup is ‘‘dried cane 

syrup.’’ This guidance is being issued 

because the term ‘‘evaporated cane 

juice’’ has appeared on a number of food 

labels in recent years. FDA’s current 

policy is that sweeteners derived from 

sugar cane syrup should not be declared 

as ‘‘evaporated cane juice’’ because that 

term falsely suggests that the sweeteners 

are juice as defined in 21 CFR 120.1(a). 

FDA is issuing this draft guidance as 

a level 1 draft guidance consistent with 

FDA’s good guidance practices 

regulation (21 CFR 10.115). The draft 

guidance, when finalized, will represent 

the agency’s current thinking on the use 

of the terms ‘‘dried cane syrup’’ and 

‘‘evaporated cane juice’’ in food 

labeling. It does not create or confer any 

rights for or on any person and does not 

operate to bind FDA or the public. An 

alternate approach may be used if such 

approach satisfies the requirements of 

the applicable statutes and regulations. 

II. Comments 

Interested persons may submit to the 

Division of Dockets Management (see 

ADDRESSES) written or electronic 

comments regarding the draft guidance. 

Submit a single copy of electronic 

comments or two paper copies of any 

mailed comments, except that 

individuals may submit one paper copy. 

Comments are to be identified with the 

docket number found in brackets in the 

heading of this document. Received 

comments may be seen in the Division 

of Dockets Management between 9 a.m. 

and 4 p.m., Monday through Friday. 

III. Electronic Access 

Persons with access to the Internet 

may obtain the draft guidance at http:// 

www.fda.gov/FoodGuidances or http:// 

www.regulations.gov. 

Dated: September 29, 2009. 

David Horowitz, 

Assistant Commissioner for Policy. 

[FR Doc. E9–24132 Filed 10–6–09; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of General Medical 

Sciences; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 


erowe on DSK5CLS3C1PROD with NOTICES
Federal Register / Vol. 74, No. 193 / Wednesday, October 7, 2009 / Notices 51611 

Name of Committee: National Institute of 

General Medical Sciences; Special Emphasis 

Panel ZGMI–MBRS–X–CH. 

Date: November 2, 2009. 

Time: 8:30 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency-Bethesda, One 

Bethesda Metro Center, Bethesda, MD 20814. 

Contact Person: John J. Laffan, PhD, 

Scientific Review Officer, Office of Scientific 

Review, National Institute of General Medical 

Sciences, National Institutes of Health, 

Natcher Building, Room 3AN18J, Bethesda, 

MD 20892, 301–594–2773, 

Iaffanjo@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.375, Minority Biomedical 

Research Support; 93.821, Cell Biology and 

Biophysics Research; 93.859, Pharmacology, 

Physiology, and Biological Chemistry 

Research; 93.862, Genetics and 

Developmental Biology Research; 93.88, 

Minority Access to Research Careers; 93.96, 

Special Minority Initiatives, National 

Institutes of Health, HHS) 

Dated: September 29, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–24029 Filed 10–6–09; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Eunice Kennedy Shriver National 

Institute of Child Health & Human 

Development; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Child Health and Human Development 

Special Emphasis Panel. Behavioral Research 

Training in Intellectual/Developmental 

Disabilities. 

Date: October 20, 2009. 

Time: 12:30 p.m. to 1:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6100 

Executive Boulevard, Room 5B01, Rockville, 

MD 20852. (Telephone Conference Call). 

Contact Person: Carla T. Walls, PhD, 

Scientific Review Officer, Division of 

Scientific Review, Eunice Kennedy Shriver 

National Institute of Child Health and 

Human Development, NIH, 6100 Executive 

Blvd., Room 5B01, Bethesda, MD 20892. 

(301) 435–6898. wallsc@mail.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.864, Population Research; 

93.865, Research for Mothers and Children; 

93.929, Center for Medical Rehabilitation 

Research; 93.209, Contraception and 

Infertility Loan Repayment Program, National 

Institutes of Health, HHS) 

Dated: October 1, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–24206 Filed 10–6–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Eunice Kennedy Shriver National 

Institute of Child Health & Human 

Development; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Child Health and Human Development 

Special Emphasis Panel; Screening for 

Inherited Disorders. 

Date: November 3, 2009. 

Time: 2 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6100 

Executive Boulevard, Room 5B01, Rockville, 

MD 20852 (Telephone Conference Call). 

Contact Person: Neelakanta Ravindranath, 

PhD, Scientific Review Officer, Division of 

Scientific Review, Eunice Kennedy Shriver 

National Institute of Child Health and 

Human Development, 6100 Executive Blvd., 

Room 5B01G, Bethesda, MD 20892–7510, 

301–435–6889. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.864, Population Research; 

93.865, Research for Mothers and Children; 

93.929, Center for Medical Rehabilitation 

Research; 93.209, Contraception and 

Infertility Loan Repayment Program, National 

Institutes of Health, HHS) 

Dated: September 29, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–24205 Filed 10–6–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Human Genome Research 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Human 

Genome Research Institute Special Emphasis 

Panel; 1000 Genomes Project Dataset 

Analysis. 

Date: October 26, 2009. 

Time: 2 p.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: NHGRI Library, 5635 Fishers Lane, 

Rockville, MD 20852. 

Contact Person: Keith McKenney, PhD, 

Scientific Review Officer, NHGRI, 5635 

Fishers Lane, Suite 4076, Bethesda, MD 

20814. 301–594–4280. 

mckenneyk@mail.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.172, Human Genome 

Research, National Institutes of Health, HHS) 

Dated: September 29, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–24204 Filed 10–6–09; 8:45 am] 

BILLING CODE 4140–01–P 


erowe on DSK5CLS3C1PROD with NOTICES